Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML)
Status:
Completed
Trial end date:
2016-12-27
Target enrollment:
Participant gender:
Summary
The hypothesis of this proposal is that combining plerixafor, an inhibitor of stromal cell
derived factor - 1α (SDF-1α), with decitabine, a DNA methyltransferase inhibitor, as
induction and postremission therapy for older patients with Acute Myeloid Leukemia (AML) will
improve treatment outcomes via mobilization of leukemia stem cells and alteration of the
pharmacodynamics of decitabine. The protocol will establish the safety and feasibility of
combining two different doses of plerixafor with a fixed dose and schedule of decitabine.